Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients

Tappero, Stefano; Sorce, Gabriele; Panunzio, Andrea; Hohenhorst, Lukas; Garcia, Cristina Cano; Piccinelli, Mattia Luca; Tian, Zhe; Parodi, Stefano; Chun, Felix K.‐H.; Graefen, Markus; Antonelli, Alessandro; Cobelli, O. De; Saad, Fred; Shariat, Shahrokh F.; Montorsi, Francesco; Suardi, Nazareno; Borghesi, Marco; Terrone, Carlo; Karakiewicz, Pierre I.

doi:10.5173/ceju.2022.142

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A National Cancer Database study published on patients with non-metastatic MIBC (T2a-T4) demonstrated neoadjuvant chemotherapy improved overall survival and pathological downstaging compared to radical cystectomy alone for patients with SV UC (n = 501, p = 0.014) [24]. Another SEER registry review of 110 patients with metastatic SV UC reported an overall survival of 8 months with chemotherapy treatment and 2 months without (p = 0.016) [25]. Thus.…”

Section: Discussionmentioning

confidence: 99%

Successful Bladder-Sparing Partial Cystectomy for Muscle Invasive Domal Urothelial Carcinoma with Sarcomatoid Differentiation: A Case Report

Sultan

Abdelaziz

Martinez

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: High Grade (HG) Urothelial Carcinoma (UC) with variant histology has historically been managed conservatively and continues to create a conundrum for clinical urologists. The presented case details a solitary lesion of Muscle Invasive Bladder Cancer (MIBC) with sarcomatoid variant (SV) histology treated by partial cystectomy and adjuvant chemotherapy without evidence of HG recurrence in 8 years of surveillance. Case Presentation: A 71-year-old male with a 15-pack year smoking history presented to clinic after outside transurethral resection of bladder tumor (TURBT). Imaging by CT abdomen and pelvis was negative for pelvic lymphadenopathy or abnormalities in either collecting system. A 2 cm broad based papillary tumor at the bladder dome was identified. Complete staging TURBT noted a final pathology of invasive HG UC with areas of spindle cell differentiation consistent with sarcomatous changes and no evidence of lymphovascular invasion. The patient was inclined toward bladder preserving options. Partial cystectomy with a 2 cm safety margin and bilateral pelvic lymphadenectomy was performed. Final pathology revealed HG UC urothelial carcinoma with sarcomatoid differentiation and invasion into the deep muscularis propria, consistent with pathologic T2bN0 disease, a negative margin, and no lymphovascular invasion. The patient subsequently pursued four doses of adjuvant doxorubicin chemotherapy though his treatment was complicated by hand-foot syndrome. The patient continued screening with cystoscopy, urine cytology, and CT. At 21 months post operatively, the patient developed a small (<1cm) papillary lesion near but uninvolved with the left ureteral orifice. Blue light cystoscopy and TURBT revealed noninvasive low grade Ta urothelial carcinoma. To date, the patient has no evidence of high-grade urothelial carcinoma recurrence; 8 years after partial cystectomy. Patient maintains good bladder function and voiding every 3-4 hours with a bladder capacity around 350 ml. Conclusion: Surgical extirpation with partial cystectomy followed by adjuvant chemotherapy may represent a durable solution for muscle invasive (pT2) UC with SV histology if tumor size and location are amenable for partial cystectomy. Due to the sparse nature of sarcomatous features within urothelial carcinoma, large multicenter studies are required to further understand the clinical significance and optimal management options for this variant histology in the management of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%